Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma

Nuclear Medicine Communications

Volumn 32, Issue 7, 2011, Pages 605-610

  Zhang, Min ^a   Guo, Rui ^a   Xu, Haoping ^a   Zhang, Miao ^a   Li, Biao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

all trans retinoic acid; radioiodine uptake; sodium iodide symporter; thyroid carcinoma; tributyrin

Indexed keywords

IODINE 125; MESSENGER RNA; RETINOIC ACID; SODIUM IODIDE SYMPORTER; TRIBUTYRIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; FOLLICULAR THYROID CARCINOMA; IN VITRO STUDY; POORLY DIFFERENTIATED THYROID CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BIOLOGICAL TRANSPORT; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE RADIOISOTOPES; SYMPORTERS; THYROID NEOPLASMS; TRETINOIN; TRIGLYCERIDES;

EID: 79958767856     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283463027     Document Type: Article

References (29)

1. Goretzki PE, Simon D, Frilling A, Witte J, Reiners G, Grussen M, et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 1994; 80:1131-1134.
2. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16:34-41.
3. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struc Biol 2001; 11:33-38. (Pubitemid 32155549)
4. Van Herle AJ, Agatep ML, Padua DN, totanes TL, Canlapan DV, Van Herle HML, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA, RO82, W-1) in vitro. J Clin Endocrinol Metab 1990; 71:755-763.
5. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mrna levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Bioph Res Co 1997; 240:832-838. (Pubitemid 28271806)
6. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004; 89:272-280. (Pubitemid 38183893)
7. Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med 2002; 29:775-782.
8. Schmutzler C, Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000; 10:393-405.
9. Coelho SM, Corbo R, Breitenbach MMD, Carvalho J, Buescu A, Carvalho DP, et al. Retinoic acid receptor (RAR) beta expression as a possible predictive factor of response to redifferentiation therapy in patients with metastatic thyroid carcinoma. Thyroid 2003; 13:730.
10. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004; 90:535-541. (Pubitemid 38258278)
11. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:3430-3435.
12. Massart C, Poirier C, Fergelot P, Fardel O, Gibassier J. Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells. Anticancer Drugs 2005; 16:255-261. (Pubitemid 40283940)
13. Taimi M, Chen ZX, Breitman TR. Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and examethylene bisacetamide. Oncol Res 1998; 10:75-84. (Pubitemid 128737114)
14. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61:1477-1485. (Pubitemid 34292576)
15. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RAR beta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002; 62:2455-2461. (Pubitemid 34462717)
16. Egorin MJ, Yuan ZM, Sentz DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 1999; 43:445-453. (Pubitemid 29187582)
17. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998; 4:629-634.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 2001; 25:402-408. (Pubitemid 34164012)
19. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114:1090-1098. (Pubitemid 14134351)
20. Massart C, Denais A, Gibassier J. Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts. Anticancer Drugs 2006; 17:559-563. (Pubitemid 44309972)
21. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, et al. Retinoic acid and the histone deacetylase inhibitor trichostatin A inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005; 11:3558-3566. (Pubitemid 40627912)
22. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391:811-814. (Pubitemid 28099682)
23. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004; 145:2865-2875. (Pubitemid 38686236)
24. Altmann A, Eisenhut M, Bauder-Wüst U, Markert A, Askoxylakis V, Hess-Stumpp H, et al. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 2010; 37:2286-2297.
25. Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E, Piampani P, et al. All-transretinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab 2005; 90:2403-2411. (Pubitemid 40586291)
26. Eigelberger MS, Wong MG, Duh QY, Clark OH. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer. Surgery 2001; 130:931-935. (Pubitemid 34014556)
27. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000; 85:2889-2896. (Pubitemid 32269169)
28. El-Metwally TH, Adrian TE. Optimization of treatment conditions for studying the anticancer effects of retinoids using pancreatic adenocarcinoma as a model. Biochem Biophys Res Commun 1999; 257:596-603. (Pubitemid 29301488)
29. Demary K, Wong L, Spanjaard RA. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 2001; 163:103-107. (Pubitemid 32121835)